Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 3Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 6Leukemia 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Leukemia, Monocytic, Acute 1

Interventions

Cyclophosphamide 14fludarabine phosphate 12ruxolitinib 9Busulfan 9Antilymphocyte Serum 9Peripheral Blood Stem Cell Transplantation 8fludarabine 7Whole-Body Irradiation 7Filgrastim 7Cyclosporine 7Tacrolimus 6Radiotherapy 6Mycophenolic Acid 6Methylprednisolone 6Methotrexate 5Melphalan 5Cord Blood Stem Cell Transplantation 5Azacitidine 5Imatinib Mesylate 4Cytarabine 4Alemtuzumab 4ponatinib 3parsaclisib 3fedratinib 3Stem Cell Transplantation 3Rituximab 3Etoposide 3Decitabine 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3venetoclax 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Myeloproliferative Disorders × CPX-351 × Clear all
NCT03878199 2026-04-24

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Ohio State University Comprehensive Cancer Center

Phase 1/2 Terminated
12 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡